Description
N-Acetyl Semax is an N-terminally acetylated analog of Semax — a synthetic heptapeptide originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow as a synthetic fragment of ACTH (residues 4-10) with a Pro-Gly-Pro C-terminal extension for peptidase resistance. Semax itself is one of the most-studied Russian-origin neuropeptides; N-Acetyl Semax further extends plasma stability through N-terminal acetylation, which protects against degradation by aminopeptidases. The compound is studied as a research analog for comparative pharmacology versus standard Semax, with particular focus on extended-half-life peptide engineering and SAR studies of N-terminal modifications in ACTH-derived heptapeptides. N-Acetyl Semax has been investigated in preclinical research literature for melanocortin receptor binding (MC3R, MC4R, MC5R), BDNF gene expression endpoints, and comparative peptide stability research. Like Semax, the compound is studied here primarily as a research tool for ACTH-derived peptide pharmacology and structure-activity relationship (SAR) studies of N-terminal modifications. This 55mg vial size is offered for extended-protocol research applications and as a bulk option for laboratories conducting comparative SAR studies.
Benefits (Research Focus)
• Melanocortin receptor pharmacology — studied for MC3R, MC4R, and MC5R receptor binding activity as an ACTH-derived peptide
• N-terminal modification SAR — investigated for the effect of N-acetylation on peptide stability and receptor activity
• BDNF pathway research — explored for BDNF gene expression endpoints in neuronal cell research models
• Plasma stability research — examined for extended plasma half-life vs standard Semax through N-acetylation peptidase protection
• Comparative Semax pharmacology — researched alongside standard Semax for comparative SAR and stability studies
What Researchers Look At
• Melanocortin receptor binding affinity and selectivity profiles across MC3R / MC4R / MC5R subtypes
• Plasma half-life and peptidase resistance research compared to standard Semax
• BDNF gene and protein expression in neuronal cell research models
• Comparative pharmacology versus standard Semax (Met-Glu-His-Phe-Pro-Gly-Pro)
• N-terminal acetylation effects on receptor binding and signaling cascades
Quick Specs
• Form: Lyophilized white powder
• Net Peptide Content: 55 mg per vial
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% by HPLC
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: N-Acetyl Semax (NA-Semax)
• Synonyms: NA Semax; Acetyl-Semax; N-Ac-MEHFPGP-NH₂; acetylated ACTH(4-10) extended analog
• Class: Synthetic heptapeptide research analog; N-terminally acetylated Semax derivative; ACTH-derived peptide
• Sequence: N-Acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂ — 7 amino acids with N-acetylation and C-amidation
• Origin: N-acetylated analog of Semax, originally developed at the Institute of Molecular Genetics, Russian Academy of Sciences (Moscow)
• Formula / M.W.: ~828.9 g/mol (verify exact formula against batch COA — Met versus Nle substitution affects sulfur content)
• CAS: N/A (research analog — standard Semax CAS is 80714-61-0)
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.
Janoshik COA — Third-Party Testing
• [COA link for the N-Acetyl Semax 55mg batch to be added once Janoshik testing is complete]
